NantKwest unveils first-in-human Phase 1 trial of its NK cell therapy
Category: #health  By Mateen Dalal  Date: 2019-06-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

NantKwest unveils first-in-human Phase 1 trial of its NK cell therapy

PD-L1 t-haNK is a natural killing cell-based immuno-oncology therapy which includes Chimeric Antigen Receptor (CAR) based on PD-L1

NantKwest, leading company in clinical-stage immunotherapy that develops activated natural killer cells (NK) to treat infectious disease and cancer, recently confirmed that PD-L1 t-haNK investigational new drug application developed by the company has cleared the FDA review and would to be used in the first-in-human clinical trial for patients suffering from metastatic or locally advanced solid cancer.

Apparently, Programmed death-ligand (PD-L1) is said to be a transmembrane protein that is essential in suppressing the immune system in several cancer patients. PD-L1 is bound to the molecules of inhibitory checkpoint PD-1 where it establishes an inhibitory signal. The proliferation of antigen-specific T-cells along with the apoptosis in regulatory T cells, that obstruct immune responses, is significantly reduced by the inhibitory signal.

Citing reliable sources, PD-L1 t-haNK is a natural killing cell-based immuno-oncology therapy which includes Chimeric Antigen Receptor (CAR) based on PD-L1. Its is developed into the company’s proprietary haNK natural killing cell, that also includes CD16 receptor’s high affinity variant which helps mediate antibody dependent cellular cytotoxicity (ADCC).

Dr. Patrick Soon-Shiong, CEO and Chairman of NantKwest announced that the company has been authorized by the FDA to go ahead with their second clinical trial of bispecific NK cell therapy that uses PD-L1 t-haNK. It will target patients suffering with solid tumors, just a few weeks after FDA cleared its first bi-specific clinical trial using a CD19 t-haNK, targeting patients with lymphoma.

The company aims to combine a broad range of immunotherapy molecules with their proprietary and multi-targeted NK cell therapy and explore its potential for integrating both adaptive and innate immune systems to achieve complete remissions that are durable.

Dr. Soon-Shiong added that NantKwest is looking forward to transitioning the program to Phase 1 human clinical trial that is designed to assess PD-L1 t-haNK cell therapy’s tolerability, efficacy and safety in patients suffering from solid tumors.

 

Source credit- https://nantkwest.com/nantkwest-launches-first-in-class-first-in-human-phase-i-clinical-trial-with-a-targeted-pd-l1-t-hank-cell-therapy-in-patients-with-solid-tumors/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
By Mateen Dalal

TPG Rise Climate Fund, the climate investing fund of TPG’s global impact investing platform TPG Rise, has recently raised its first close of $5.4 billion, bringing together an exclusive blend of funding from some of the top institutional invest...

Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
By Mateen Dalal

ByHeart, a fully integrated infant nutrition company, has reportedly secured $90 million in Series B funding which the company plans to use for the launch of its baby formula and support the development of its pipeline of nutrition items for chi...

UAE extends travel ban for Indians amid strict COVID-19 guidelines
UAE extends travel ban for Indians amid strict COVID-19 guidelines
By Mateen Dalal

United Arab Emirates (UAE) has reportedly extended travel ban for individuals travelling from India and several other south Asian countries on the pretext of COVID-19 guidelines. As reported by Etihad Airlines, the ban will be followed till 31st July...